Mirtazapine: a review of its use in major depression and other psychiatric disorders

CNS Drugs. 2009;23(5):427-52. doi: 10.2165/00023210-200923050-00006.


Mirtazapine (Remeron, Zispin) is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is approved in many counties for use in the treatment of major depression. Monotherapy with mirtazapine 15-45 mg/day leads to rapid and sustained improvements in depressive symptoms in patients with major depression, including the elderly. It is as effective as other antidepressants and may have a more rapid onset of action than selective serotonin reuptake inhibitors (SSRIs). Furthermore, it may also have a higher sustained remission rate than amitriptyline. Preliminary data suggest that mirtazapine may also be effective in the treatment of anxiety disorders (including post-traumatic stress disorder, panic disorder and social anxiety disorder), obsessive-compulsive disorder, undifferentiated somatoform disorder and, as add-on therapy, in schizophrenia, although large, well designed trials are needed to confirm these findings. Mirtazapine is generally well tolerated in patients with depression. In conclusion, mirtazapine is an effective antidepressant for the treatment of major depression and also has the potential to be of use in other psychiatric indications.

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Antidepressive Agents, Tricyclic / therapeutic use*
  • Anxiety Disorders / drug therapy*
  • Databases, Bibliographic / statistics & numerical data
  • Depressive Disorder, Major / drug therapy*
  • Humans
  • Mianserin / analogs & derivatives*
  • Mianserin / therapeutic use
  • Mirtazapine
  • Psychiatric Status Rating Scales


  • Antidepressive Agents, Tricyclic
  • Mianserin
  • Mirtazapine